BiotechTube

Rivaroxaban (Xarelto,Bay 59-7939) + Acetylsalicylic acid(ASA)

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prevention of Atherothrombotic Events

Conditions

Prevention of Atherothrombotic Events, Coronary Artery Disease (CAD), Symptomatic Peripheral Artery Disease (Symptomatic PAD)

Trial Timeline

Feb 25, 2022 → Jun 6, 2024

NCT ID
NCT04298567

About Rivaroxaban (Xarelto,Bay 59-7939) + Acetylsalicylic acid(ASA)

Rivaroxaban (Xarelto,Bay 59-7939) + Acetylsalicylic acid(ASA) is a pre-clinical stage product being developed by Bayer for Prevention of Atherothrombotic Events. The current trial status is completed. This product is registered under clinical trial identifier NCT04298567. Target conditions include Prevention of Atherothrombotic Events, Coronary Artery Disease (CAD), Symptomatic Peripheral Artery Disease (Symptomatic PAD).

What happened to similar drugs?

5 of 20 similar drugs in Prevention of Atherothrombotic Events were approved

Approved (5) Terminated (0) Active (15)
🔄edoxaban + enoxaparin sodiumDaiichi SankyoPhase 3
🔄DAPA/MET XR + DAPA + MET XRAstraZenecaPhase 3
🔄Esomeprazole + PlaceboAstraZenecaPhase 3
✅RaltegravirMerckApproved
🔄RotaTeq (V260) + IPVMerckPhase 3
🔄V501MerckPhase 3
🔄ZostavaxMerckPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04298567Pre-clinicalCompleted

Competing Products

20 competing products in Prevention of Atherothrombotic Events

See all competitors
ProductCompanyStageHype Score
mRNA-1944ModernaPhase 1
0
Gam-COVID-VacDr. Reddy's LaboratoriesPhase 2/3
31
edoxaban + enoxaparin sodiumDaiichi SankyoPhase 3
40
MifepristoneEli LillyPhase 2
35
EXANTAAstraZenecaPhase 2
27
Risk of low dose aspirin discontinuationAstraZenecaPre-clinical
26
DAPA/MET XR + DAPA + MET XRAstraZenecaPhase 3
40
Esomeprazole + PlaceboAstraZenecaPhase 3
40
PCV15MerckPre-clinical
18
RaltegravirMerckApproved
43
RotaTeq (V260) + IPVMerckPhase 3
40
V501MerckPhase 3
40
ZostavaxMerckPhase 3
40
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920MerckPhase 3
40
Letermovir + PlaceboMerckPhase 3
40
Meningococcal C conjugate vaccineNovartisApproved
43
Enteric-coated mycophenolate sodiumNovartisPhase 3
40
Meningococcal C conjugate vaccineNovartisApproved
43
rMenB+OMV NZNovartisPhase 3
40
Enteric-Coated Mycophenolate SodiumNovartisPhase 3
40